Texas Children’s Hospital, the largest pediatric medical center in the country, has been compelled by the state of Texas to open the nation’s first ever “detransition clinic,” a stunning turn for an institution that spent years insisting it had already stopped performing so-called gender-affirming procedures on minors. The settlement, reached with Texas Attorney General Ken Paxton’s office, closes out a three-year investigation that began in 2023 and represents one of the most consequential accountability actions taken against a major hospital system on this issue anywhere in the country.
Under the terms of the deal, Texas Children’s must open the detransition clinic within a defined window after the settlement takes effect. The clinic will be required to provide a full range of services to those who received transition-related treatment as minors, including endocrinology, surgery, primary care, fertility counseling, psychiatry, psychotherapy, social work and case management, and speech pathology. For adults above the age of twenty-one who previously received transition procedures, the hospital must also provide obstetric and gynecological care. Critically, the hospital must offer these detransition services free of charge for the first five years the clinic operates.
The investigation traces back to May 2023, when Paxton’s office first announced it was examining the hospital following public reporting that raised questions about its gender clinic practices. At the time, Paxton stated plainly that any procedures harming children under the banner of gender transitioning amounted to child abuse under Texas law. That same year, Governor Greg Abbott signed Senate Bill 14, which barred puberty blockers and cross-sex hormone treatments for minors statewide, closing off the legal pathway for hospitals to continue offering such interventions to children.
What makes this case especially notable is that Texas Children’s had publicly claimed as far back as 2022 that it had already shut down its transgender clinic. That claim was directly contradicted by whistleblower Dr. Eitan Haim, a general surgery resident who came forward with evidence that the hospital was continuing to provide puberty blockers to children as young as eleven, allegedly in secret, even after telling the public and lawmakers that the program had ended. Haim’s disclosures set off a political and legal firestorm, and rather than facing consequences for exposing the practice, he found himself the target of scrutiny from federal health privacy regulators, a dynamic that conservatives have pointed to as emblematic of how whistleblowers on this issue are too often treated.
The final settlement, whose full details were only released this month after months of the agreement sitting unsigned, requires Texas Children’s to pay a substantial financial penalty to the state. Figures reported by outlets covering the settlement place the payment at more than eight and a half million dollars, with earlier reporting citing a headline figure of ten million dollars tied to allegations that the hospital improperly billed the state’s Medicaid program using false diagnosis codes for gender transition interventions. Either way, the message from Austin was unmistakable: taxpayer-funded healthcare programs will not be permitted to underwrite procedures that lawmakers have determined are harmful to children.
Beyond the financial penalty, the settlement forces the permanent revocation of medical privileges for multiple physicians tied to the hospital’s gender program, three current doctors and two former ones, according to the settlement terms. The hospital must also amend its own bylaws so that any physician found violating the state’s prohibition on so-called gender transition interventions for minors automatically loses admitting and treatment privileges going forward. This is not a symbolic gesture. It builds an enforcement mechanism directly into the hospital’s own governance structure, making it far harder for the practice to quietly resume under a future administration or a new set of doctors.
Texas Children’s is also required to formally attest, in writing, that it has permanently and irrevocably ceased providing what the settlement terms “sex rejecting procedures,” unless a future change in state law were to require otherwise. That is about as unambiguous a concession as a hospital system can make, and it stands as a direct repudiation of years of public statements from hospital administrators who insisted their practices were lawful and appropriate.
Perhaps the most unusual element of the settlement is the creation of two permanent patient tracking lists. The first, referred to in settlement documents as the “Break the Glass” list, will include every patient the hospital ever treated who received a gender dysphoria diagnosis. The second will track those considered potential candidates for gender-related care. Both lists must be maintained for a minimum of ten years, refreshed annually, and patients cannot be removed from them once added. Supporters of the settlement argue this ensures accountability and gives families a mechanism to be reached if complications or the need for corrective care arise down the road. Critics of the broader gender medicine field have long argued that hospitals kept insufficient records on outcomes for these patients, and this provision appears designed to close that gap permanently.
Paxton did not mince words in announcing the deal, calling it a monumental day in what he described as the fight to stop the radical transgender movement from reaching into pediatric medicine. His office emphasized that the settlement was secured in coordination with the Department of Justice under President Trump, underscoring how federal and state efforts have increasingly aligned on this issue since the change in administration in January 2025.
It is worth noting that the population directly affected by this settlement is small in absolute terms. Data cited from the Williams Institute estimates that only about 3.3 percent of Texas youth between thirteen and seventeen identify as transgender, and separate research suggests that only a tiny fraction, roughly one tenth of one percent, of minors nationally ever received transition-related medical care before Texas banned it for minors in 2023. Hospital defenders have pointed to these numbers to argue the program was already limited in scope. But for conservatives who have pushed this issue for years, the small numbers do not diminish the significance of forcing accountability. If even a handful of children were subjected to irreversible medical interventions based on immature or mistaken beliefs about their gender identity, advocates argue, the harm done justifies exactly this kind of reckoning.
The settlement does leave certain treatments available. Hormone therapies will continue to be offered to cisgender minors for legitimate medical conditions unrelated to gender transition, a distinction the settlement is careful to preserve so that children with genuine endocrine disorders are not caught up in the restrictions meant to target transition-specific care.
Advocacy groups on the political left have criticized the settlement, framing it as evidence of politics overriding medical judgment and expressing concern that families who want ongoing support for their children will now face a more restrictive landscape. Those concerns have received relatively little traction in Texas, where lawmakers passed Senate Bill 14 with strong majorities and where public polling has consistently shown skepticism among Texans, particularly parents, about administering hormonal or surgical interventions to minors experiencing gender dysphoria.
The case also intersects with a broader national conversation. Multiple other states have pursued similar bans on pediatric gender transition procedures, and legal challenges to those laws have worked their way through federal courts, with the Supreme Court in 2025 upholding Tennessee’s ban on such treatments for minors in a closely watched ruling. That decision gave state attorneys general like Paxton additional legal footing to pursue enforcement actions of this kind against hospitals that appeared to be operating in violation of, or in defiance of, state law.
For families whose children went through the hospital’s gender program before the ban took effect, the new detransition clinic represents the first formal avenue for institutional support should they choose to reverse or discontinue treatment. Detransition, the settlement documents note, remains statistically rare, but the very existence of a dedicated clinic marks a significant philosophical shift for a major hospital system, one that had for years built its public messaging around the idea that gender-affirming care was the appropriate and often necessary standard of treatment.
Conservative commentators have framed the settlement as a template other states can now use. Paxton’s office has pursued parallel investigations into other hospital systems in Texas, and legal observers expect attorneys general in other red states to look closely at the structure of this settlement, particularly its automatic privilege revocation clause and its permanent patient tracking requirement, as a model for their own enforcement efforts.
The settlement also lands amid continuing scrutiny of pediatric gender medicine more broadly. Federal health officials under the current administration have signaled interest in reviewing clinical guidelines that for years shaped how major medical associations approached adolescent gender dysphoria, guidelines that critics argue were adopted with insufficient evidence and are now being revisited in several Western countries, including the United Kingdom, which conducted its own extensive review and moved to restrict puberty blockers for minors outside of clinical trials.
Texas Children’s, for its part, has said publicly that it believes it complied with all applicable laws throughout the period in question and that it chose to settle in order to close what it described as a chapter marked by falsehoods and distraction. Whether that framing satisfies skeptics who point to Dr. Haim’s whistleblower account remains an open question, one that will likely continue to be debated as the detransition clinic opens its doors later this year.
